logo

For the Inventor, By the Inventor

Somerset, NJ, United States of America

Michael Orsini

This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignee: Janssen Pharmaceutica Nv. Active years: 2006-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael Orsini. Retrieved from https://idiyas.com/inventor/michael-orsini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4

% Patents Active = 75.0


Average Co-Inventor Count = 7.4

ph-index = 3

Forward Citations = 12(Granted Patents)


Company Filing History:

goldMedal4 out of 2,101 
 
Janssen Pharmaceutica Nv
 patents

Years Active: 2006-2014

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents
1. 8778956 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders (2014-07-15),
2. 7655670 - 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators (2010-02-02),
3. 7582649 - Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders (2009-09-01),
4. 7081463 - Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders (2006-07-25),

Title: Michael Orsini: Innovator in Pharmaceutical Chemistry

Introduction

Michael Orsini is a notable inventor based in Somerset, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds for medical applications. With a total of 4 patents to his name, Orsini's work focuses on innovative solutions for treating various disorders.

Latest Patents

Among his latest patents, Orsini has developed hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives, which are useful for the treatment of ORL-1 receptor mediated disorders. This invention is directed towards novel compounds that can potentially improve therapeutic outcomes for patients. Additionally, he has created 3-spirocyclic indolyl derivatives that serve as ORL-1 receptor modulators. These compounds, along with their pharmaceutical compositions, are aimed at treating disorders and conditions modulated by the ORL-1 receptor.

Career Highlights

Michael Orsini is currently employed at Janssen Pharmaceutica NV, where he continues to push the boundaries of pharmaceutical innovation. His work has been instrumental in advancing the understanding and treatment of complex medical conditions.

Collaborations

Orsini collaborates with esteemed colleagues, including Kathleen A Battista and Gilles C Bignan, to further enhance the impact of his research and inventions.

Conclusion

Michael Orsini's contributions to pharmaceutical chemistry exemplify the spirit of innovation in the field. His patents and ongoing research hold promise for improving treatment options for various disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…